You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Claims for Patent: 10,550,098

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,550,098

Title:	Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Abstract:	The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:
Inventor(s):	Lin Jian, Ericsson Anna, Campbell Ann-Marie, Gustafson Gary, Wang Zhongguo, Diebold R. Bruce, Ashwell Susan, Lancia, Jr. David R., Caravella Justin Andrew, Lu Wei
Assignee:	Forma Therapeutics, Inc.
Application Number:	US16290240
Patent Claims:	2. The composition of claim 1 , wherein the process further comprises obtaining Intermediate III-1 from 5-fluoro-6-oxo-1 claim 1 ,6-dihydropyridine-2-carbonitrile.3. The composition of claim 2 , wherein the process further comprises obtaining 5-fluoro-6-oxo-1 claim 2 ,6-dihydropyridine-2-carbonitrile from 6-cyano-3-fluoropyridin-2-yl acetate.4. The composition of claim 3 , wherein the process further comprises obtaining 6-cyano-3-fluoropyridin-2-yl acetate from 2-cyano-5-fluoropyridine-1-oxide.5. The composition of claim 4 , wherein the process further comprises obtaining 2-cyano-5-fluoropyridine-1-oxide from 5-fluoropicolinonitrile.6. The composition of claim 1 , wherein the process further comprises obtaining Intermediate II-1 claim 1 , or a salt thereof claim 1 , from (R)—N—((S)-1-(2 claim 1 ,6-dichloroquinolin-3-yl)ethyl)-2-methylpropane-2-sulfinamide.7. The composition of claim 6 , wherein the process further comprises obtaining (R)—N—((S)-1-(2 claim 6 ,6-dichloroquinolin-3-yl)ethyl)-2-methylpropane-2-sulfinamide from (R claim 6 ,E)-N-((2 claim 6 ,6-dichloroquinolin-3-yl)methylene)-2-methylpropane-2-sulfinamide.8. The composition of claim 7 , wherein the process further comprises obtaining (R claim 7 ,E)-N-((2 claim 7 ,6-dichloroquinolin-3-yl)methylene)-2-methylpropane-2-sulfinamide from 2 claim 7 ,6-dichloroquinoline-3-carbaldehyde.17. The method of claim 10 , wherein the suitable methylating agent is MeI.18. The method of claim 11 , wherein the suitable base is KCO.19. The method of claim 13 , wherein the suitable oxidizing agent is m-CPBA.20. The method of claim 14 , wherein the suitable acid is HCl.22. The composition of comprising Compound I-13 and Intermediate II-1 or a salt thereof.23. The composition of comprising Compound I-13 and Intermediate III-1.24. The composition of comprising Compound I-13 claim 21 , Intermediate II-1 or a salt thereof claim 21 , and Intermediate III-1.25. The composition of claim 21 , wherein Compound I-13 is obtained by a process comprising a step of reacting Intermediate II-1 or a salt thereof and Intermediate III-1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.